205 compound-focused publications · 20 studies with detailed explanations.
Click a paper title or Read summary to open its reading page. Find a detailed explanation or a short, attributed abstract excerpt, then follow the original source for the full conclusion.
205 of 205 publications · Showing 1–30
Demirtaş H · International journal of molecular sciences
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Zhang H, Shao L, Feng Q et al. · Applied biochemistry and biotechnology
Why included: BPC-157 fusion expression was evaluated in bacteria and a rat gastric-ulcer model.
Journal Article
Arunim, Dagar M, Solanki M et al. · 3 Biotech
Why included: The compound is a named subject of the publication title.
Journal Article
Biçer O, Adanir O, Güleryüz Y et al. · Joint diseases and related surgery
Why included: The compound is a named subject of the publication title.
Journal Article
Vukoja I, Vlainic J, Francina M et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
Why included: BPC-157 treatment was tested in a rat gentamicin kidney-injury experiment.
Journal Article
Smoday IM, Vukovic V, Oroz K et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article
Mazzarino M, Colpaert T, Deventer K et al. · The Analyst
Why included: An analytical blood-sample study measured BPC-157 detection and stability; it did not test therapeutic benefit.
Journal Article
Jelińska J, Józwiak M, Szeleszczuk Ł et al. · International journal of molecular sciences
Why included: The compound is a named subject of the publication title.
Journal Article
Yıldırım AK, Demirtaş H, Özer A et al. · Scientific reports
Why included: The compound is a named subject of the publication title.
Journal Article
Mateescu DM, Gavrilescu DM, Constantinescu FE et al. · Pharmaceutics
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Yildirim AK, Dastan AO, Demeli Ertus M et al. · Journal of clinical medicine
Why included: The compound is a named subject of the publication title.
Journal Article
Sikiric P, Barisic I, Udovicic M et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Yuan C, Demers A, Silva-Ortiz V et al. · International journal of molecular sciences
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Grubisic MM, Strbe S, Barisic I et al. · Current neuropharmacology
Why included: The compound is a named subject of the publication title.
Journal Article
Matek D, Matek I, Japjec M et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Sikiric P, Barisic I, Udovicic M et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Zhang J, Liu M, Ou H et al. · Cell communication and signaling : CCS
Why included: The compound is a named subject of the publication title.
Journal Article
Smoday IM, Vukovic V, Oroz K et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article
Madzarac G, Becejac T, Penovic T et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article
Masnec S, Kokot A, Kralj T et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article · Review
McGuire FP, Martinez R, Lenz A et al. · Current reviews in musculoskeletal medicine
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Whitehouse M · Inflammopharmacology
Why included: The compound is a named subject of the publication title.
Journal Article
Vasireddi N, Hahamyan H, Salata MJ et al. · HSS journal : the musculoskeletal journal of Hospital for Special Surgery
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Sikiric P, Seiwerth S, Skrtic A et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Sikiric P, Seiwerth S, Skrtic A et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Lee E, Burgess K · Alternative therapies in health and medicine
Why included: The compound is a named subject of the publication title.
Journal Article
Józwiak M, Bauer M, Kamysz W et al. · Pharmaceuticals (Basel, Switzerland)
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Demirtaş H, Özer A, Yıldırım AK et al. · Medicina (Kaunas, Lithuania)
Why included: The compound is a named subject of the publication title.
Journal Article
Grubisic MM, Strbe S, Barisic I et al. · Current neuropharmacology
Why included: The compound is a named subject of the publication title.
Retracted publication — read the linked retraction before using these findings.
Journal Article · Retracted Publication
Matek D, Matek I, Staresinic E et al. · Pharmaceutics
Why included: The compound is a named subject of the publication title.
Journal Article
The authors reported no measured changes of concern in these two participants. This very small, short observation cannot establish general safety, detect uncommon events, or describe long-term effects.
Two selected previous users and only three days of follow-up cannot establish safety, detect uncommon harms, or support other routes of administration.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee E et al. · Alternative therapies in health and medicine · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40131143 · PubMedOpen study summaryThe improvement reports came from patient ratings without a comparison group. The design cannot separate the peptide's effect from the procedure, expectations, or changes over time.
No randomization or control group; subjective reports cannot isolate a peptide effect or establish long-term safety.
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Lee E et al. · Alternative therapies in health and medicine · 2024
Why included: The compound is a named subject of the publication title.
Read the original study PMID 39325560 · PubMedOpen study summaryResponses improved in some early assessments, but not the later formalin phase. The result should not be presented as sustained or general pain relief.
Brief experimental pain responses do not demonstrate durable clinical analgesia or treatment safety.
The anti-nociceptive effect of BPC-157 on the incisional pain model in rats.
Jung YH et al. · Journal of dental anesthesia and pain medicine · 2022
Why included: The compound is a named subject of the publication title.
Read the original study PMID 35449779 · PubMedOpen study summaryReported improvement was subjective and there was no untreated comparison group. The combination group cannot isolate BPC-157's contribution; the study did not demonstrate cartilage repair.
Uncontrolled, subjective follow-up cannot establish efficacy. Combined treatment in some patients prevents attribution to BPC-157 alone.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Lee E et al. · Alternative therapies in health and medicine · 2021
Why included: The compound is a named subject of the publication title.
Read the original study PMID 34324435 · PubMedOpen study summaryThe findings concern a deliberately created tendon-muscle separation. Changes in signaling markers accompany repair but do not by themselves establish which pathway caused it.
A deliberately separated rat muscle–tendon junction is not a human sports injury. These results do not establish clinical recovery or safety.
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats.
Japjec M et al. · Biomedicines · 2021
Why included: The compound is a named subject of the publication title.
Read the original study PMID 34829776 · PubMedOpen study summaryRelaxation was largely dependent on the vessel's endothelial lining and nitric oxide under the tested conditions, with slight residual relaxation at the highest concentration after the lining was removed. This isolated-tissue mechanism does not establish blood-pressure or cardiovascular outcomes in people.
Isolated vessels and cells do not establish cardiovascular benefit or safety in people.
Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway.
Hsieh MJ et al. · Scientific reports · 2020
Why included: The compound is a named subject of the publication title.
Read the original study PMID 33051481 · PubMedOpen study summaryThe experiments connected vascular measurements with a possible signaling pathway. Improved blood flow in a rat injury model does not establish circulation or healing benefits in people.
Cultured human cells remain preclinical evidence. These models do not establish clinical benefit or validate a commercial research preparation.
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
Hsieh MJ et al. · Journal of molecular medicine (Berlin, Germany) · 2017
Why included: The compound is a named subject of the publication title.
Read the original study PMID 27847966 · PubMedOpen study summaryRepair and signaling measurements were associated in this model. Those markers alone do not prove a universal mechanism or establish treatment of fistulas in people.
Four-day outcomes in surgically injured rats cannot establish clinical fistula treatment or long-term safety.
Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy.
Cesarec V et al. · European journal of pharmacology · 2013
Why included: The compound is a named subject of the publication title.
Read the original study PMID 23220707 · PubMedOpen study summaryThe observed changes concerned cell movement and survival. Direct proliferation did not increase in the tested cultures, so more outgrowth should not be read as proof that BPC-157 simply makes tendon cells multiply.
Isolated rat tissue and cell behavior do not establish injury recovery or safety in people.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Chang CH et al. · Journal of Applied Physiology · 2011
Why included: The compound is a named subject of the publication title.
Read the original study PMID 21030672 · PubMedOpen study summarySeveral repair measurements favored the treated animals in this model. A deliberately cut rat ligament is different from typical human sprains, and the results do not predict a person's recovery time.
A surgically injured rat ligament does not establish healing or safety in people.
Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.
Cerovecki T et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2010
Why included: The compound is a named subject of the publication title.
Read the original study PMID 20225319 · PubMedOpen study summaryFunctional and tissue findings favored the treated rats. These outcomes concern severe experimental nerve injury and reconstruction, rather than proof of nerve regeneration in people.
Surgical nerve injury in rats does not establish recovery of human neuropathy or nerve injuries.
Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.
Gjurasin M et al. · Regulatory peptides · 2010
Why included: The compound is a named subject of the publication title.
Read the original study PMID 19903499 · PubMedOpen study summaryMuch of the experiment concerns exposure before trauma, rather than treatment started after an unexpected injury. It does not establish neurological recovery after human head injury.
Much of the experiment involved treatment before injury. Brief mouse follow-up cannot establish human concussion recovery, neurological benefit, or long-term safety.
Traumatic brain injury in mice and pentadecapeptide BPC 157 effect.
Tudor M et al. · Regulatory peptides · 2010
Why included: The compound is a named subject of the publication title.
Read the original study PMID 19931318 · PubMedOpen study summaryVessel-related changes occurred in injured rat tissue, while the cultures showed no direct vessel-growth effect. The result depended on the model and should not be described as a universal angiogenic effect.
Different outcomes in culture and animals underline the importance of model context. These experiments do not establish human injury recovery.
Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.
Brcic L et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2009
Why included: The compound is a named subject of the publication title.
Read the original study PMID 20388964 · PubMedOpen study summaryInflammation and bone-loss findings differed from controls, but blood flow in healthy gums did not change. The paper does not establish treatment of human gum disease.
An induced rodent periodontal lesion is not a clinical trial of human gum disease.
Antiinflammatory effect of BPC 157 on experimental periodontitis in rats.
Keremi B et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2009
Why included: The compound is a named subject of the publication title.
Read the original study PMID 20388954 · PubMedOpen study summaryThe results describe structural adaptation and healing after rat surgery. They do not directly show restored nutrient absorption or outcomes after human bowel resection.
Surgically induced short bowel in rats does not establish treatment outcomes or nutritional recovery in people.
Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats.
Sever M et al. · Digestive diseases and sciences · 2009
Why included: The compound is a named subject of the publication title.
Read the original study PMID 19093208 · PubMedOpen study summaryThe paper reports repair-related changes after a controlled crush injury. It does not measure athletic recovery or return to activity in people.
A short experimental rat injury study does not establish human injury recovery.
Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat.
Novinscak T et al. · Surgery today · 2008
Why included: The compound is a named subject of the publication title.
Read the original study PMID 18668315 · PubMedOpen study summaryThe study's results are from rat experiments. References to clinical development in its introduction do not turn these experiments into a human ulcer trial.
Despite references to human ulcers in the abstract, the reported experiments were in rats. Their results do not establish human ulcer healing.
Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.
Xue XC et al. · World journal of gastroenterology · 2004
Why included: The compound is a named subject of the publication title.
Read the original study PMID 15052688 · PubMedOpen study summaryThe reported effects involved several aspects of repair in this surgical rat model, rather than a single cell marker. Mechanical measurements describe the tested tendon; they do not predict recovery time for a person with a tendon injury.
Surgically injured rat tendons are not clinical human injuries. Follow-up was short, and these findings do not establish long-term safety or efficacy in people.
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
Staresinic M et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003
Why included: The compound is a named subject of the publication title.
Read the original study PMID 14554208 · PubMedOpen study summaryThe paper addresses wound healing within a particular burn-and-steroid model. It cannot establish reversal of steroid-related healing problems in patients.
Mouse burns, a topical preparation, and concurrent corticosteroids are a specific experimental setting. Findings do not establish clinical burn care or effects through other routes.
Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice.
Sikiric P et al. · Burns : journal of the International Society for Burn Injuries · 2003
Why included: The compound is a named subject of the publication title.
Read the original study PMID 12781609 · PubMedOpen study summaryThe findings involved a specific mouse burn model and experimental preparations. They cannot establish the performance of a commercial cream or clinical burn treatment.
Animal wound outcomes cannot establish clinical burn treatment, formulation equivalence, or human safety.
Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice.
Mikus D et al. · Burns : journal of the International Society for Burn Injuries · 2001
Why included: The compound is a named subject of the publication title.
Read the original study PMID 11718984 · PubMedOpen study summary